Here are four things to know about the clinical trial.
1. The two-year trial, one of the first of its kind, will investigate whether a UPMC-developed molecular genetic test, ThyroSeq, can differentiate between thyroid cancers requiring full resection of the thyroid gland and cancers requiring less invasive procedures.
2. Thyroid-preserving surgery aims to lower surgical complications and keep patients from taking daily medication to sustain normal hormone levels.
3. A scientific team lead by Yuri Nikiforov, MD, PhD, director of UPMC’s division of molecular and genomic pathology and co-director of the medical center’s multidisciplinary thyroid center, developed the test. UPMC’s latest version allows pathologists to simultaneously test 14 genes for 42 markers of thyroid cancer using cells collected during initial biopsy.
4. Scientists plan to enroll about 100 patients newly diagnoses with thyroid cancer in the trial.
More articles on healthcare quality:
Nearly half of HIV-positive blacks do not receive regular medical treatment
Routinely prescribed antibiotic may not be best severe C. diff treatment
Mothers who deliver preterm infants at higher risk for heart disease later in life
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
